Table 1.

Clinical Trial Characteristics

ReferenceDesignNBaseline IRLS Mean+SDFollow-up (weeks)Drug/DoseAdjusted Mean Difference IRLS Mean+SETreatment CGI-I Responder Rate (%)Jadad Score
CGI-I = Clinical Global Impression – Improvement scale; DB = double-blind; IRLS = International Restless Legs Syndrome Study Group scale; N/A=not available; P=prospective; PC=placebo control; R=randomized.
Allen (2004)17P, R, DB, PC55N/A12Ropinirole 0.25–4.0 mg/d–1.2±2.1Ropinirole=17/32 (53)
 Placebo=17/33 (52)3
Stiasny-Kolster (2004)18P, R, DB, PC6325.0 ± 5.01Rotigotine 1.125–4.5 mg/24 hN/ARotigotine=34/49 (69)
 Placebo=6/14 (43)4
Trenkwalder (2004)19P, R, DB, PC28424.4 ± 5.812Ropinirole 0.25–4.0 mg/d–3.0±1.1Ropinirole=78/146 (53)
 Placebo=56/138 (41)4
Walters (2004)20P, R, DB, PC26723.6 ± 5.912Ropinirole 0.25–4.0 mg/d–2.5±1.1Ropinirole=78/131 (60)
 Placebo=53/135 (39)5
Bogan (2006)21P, R, DB, PC38122.0 ± 5.012Ropinirole 0.25–4.0 mg/d–3.7±0.9Ropinirole=137/187 (73)
 Placebo=109/193 (56)5
Inoue (2006)22P, R, DB, PC41N/A6Pramipexole 0.125–0.75 mg/d–11.5±3.0Pramipexole=16/20 (80)
 Placebo=11/21 (52)3
Partinen (2006)23P, R, DB, PC10722.7 ± 4.13Pramipexole 0.125–0.75 mg/d–9.2±1.7Pramipexole=65/86 (76)
 Placebo=9/21 (43)3
Winkelman (2006)24P, R, DB, PC33923.4 ± 5.112Pramipexole 0.25–0.75 mg/d–4.3±1.1Pramipexole=183/254 (72)
 Placebo=44/85 (52)4
Garcia-Borreguero (2007)25P, R, DB. PC27025.48Sumanirole 0.5–4.0 mg/dN/ASumanirole=104/212 (49)
 Placebo=26/51 (51)3
Oertel (2007)26P, R, DB. PC34128.0 ± 6.36Rotigotine 0.5–4 mg/24 hN/ARotigotine=212/280 (76)
 Placebo=29/53 (55)5
Oertel (2007)27P, R, DB. PC33824.7 ± 5.26Pramipexole 0.125–0.75 mg/d–6.6±1.1Pramipexole=141/224 (63)
 Placebo=37/114 (32)3
RRL10001328P, R, DB, PC35926.0 ± 4.412Ropinirole 0.5–6.0 mg/d–4.1±1.0Ropinirole=124/175 (71)
 Placebo=92/184 (50)4
ROP10189229P, R, DB, PC29823.5 ± 6.212Ropinirole 0.25–4.0 mg/dN/ARopinirole=92/152 (61)
 Placebo=76/146 (52)4
SKF10146830P, R, DB, PC5426.6 ± 5.37Ropinirole 0.25–4.0 mg/d–9.9±2.9N/A3